Raj K. Puri's most recent trade in Iovance Biotherapeutics Inc was a trade of 5,469 Common Stock done . Disclosure was reported to the exchange on June 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2025 | 5,469 | 212,321 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2025 | 5,469 | 38,287 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.76 per share. | 02 Jun 2025 | 2,467 | 209,854 (0%) | 0% | 1.8 | 4,342 | Common Stock |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Purchase of securities on an exchange or from another person at price $ 1.74 per share. | 23 May 2025 | 5,600 | 206,852 (0%) | 0% | 1.7 | 9,743 | Common Stock |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 8,334 | 0 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 8,334 | 203,761 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.59 per share. | 14 Mar 2025 | 2,509 | 201,252 (0%) | 0% | 3.6 | 9,007 | Common Stock |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 117,190 | 117,190 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 59,999 | 43,756 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 59,999 | 215,411 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.04 per share. | 03 Mar 2025 | 19,984 | 195,427 (0%) | 0% | 4.0 | 80,735 | Common Stock |
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | 16 Dec 2024 | 8,334 | 8,334 | - | - | Restricted Stock Units | ||
| Iovance Biotherapeutics Inc | Raj Puri K. | Chief Regulatory Officer | 16 Dec 2024 | 8,334 | 159,171 (0%) | 0% | 0 | Common Stock | ||
| Iovance Biotherapeutics Inc | Raj K. Puri | Chief Regulatory Officer | 16 Dec 2024 | 3,759 | 155,412 (0%) | 0% | 7.8 | 29,471 | Common Stock |